Day One Biopharmaceuticals, Inc. (DAWN) Earnings History
Annual and quarterly earnings data from 2019 to 2025
Loading earnings history...
DAWN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
DAWN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 89.1% | -80.8% | -67.8% |
| 2024 | 96.0% | -165.7% | -72.8% |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export DAWN earnings history in CSV or JSON format
Free sign-in required to download data
Day One Biopharmaceuticals, Inc. (DAWN) Earnings Overview
As of May 6, 2026, Day One Biopharmaceuticals, Inc. (DAWN) reported trailing twelve-month net income of -$107M, reflecting -2.0% year-over-year growth. The company earned $-1.04 per diluted share over the past four quarters, with a net profit margin of -67.8%.
Looking at the long-term picture, DAWN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$13M in fiscal 2019.
Day One Biopharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including KURA (-$279M net income, -412.9% margin), TGTX ($60M net income, 7.1% margin), IMVT (-$464M net income), DAWN has outperformed on profitability metrics. Compare DAWN vs KURA →
DAWN Earnings vs Peers
Earnings metrics vs comparable public companies
DAWN Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$107M | -12.4% | -$128M | $-1.04 | -67.8% | -80.8% |
| 2024 | -$95M | +49.5% | -$217M | $-1.02 | -72.8% | -165.7% |
| 2023 | -$189M | -32.9% | -$206M | $-2.37 | - | - |
| 2022 | -$142M | -101.3% | -$147M | $-2.02 | - | - |
| 2021 | -$71M | -74.4% | -$73M | $-1.14 | - | - |
| 2020 | -$41M | -220.6% | -$14M | $-0.65 | - | - |
| 2019 | -$13M | - | -$15M | $-0.24 | - | - |
See DAWN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DAWN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare DAWN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonDAWN — Frequently Asked Questions
Quick answers to the most common questions about buying DAWN stock.
Is DAWN growing earnings?
DAWN EPS of $-1.04 reflects slowing growth at -2.0%, below the 5-year CAGR of N/A. TTM net income is $-107M. Expansion rate has moderated.
What are DAWN's profit margins?
Day One Biopharmaceuticals, Inc. net margin is -67.8%, with operating margin at -80.8%. Below-average margins reflect competitive or cost pressures.
How consistent are DAWN's earnings?
DAWN earnings data spans 2019-2025. The current earnings trend is -2.0% YoY. Historical data enables comparison across business cycles.